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Summary
We describe here a monoclonal antibody (H398) that immunoprecipitates ahuman60-kDtumor
necrosis factor (TNF) membrane receptor (p60) and competes with TNF binding to p60 but
not to p85 TNF receptors. Despite partial inhibition ofTNF binding capacity of cells coexpress-
ing both TNF receptor molecules, H398 uniformly and completely inhibits very distinct TNF
responses on a variety of cell lines. These data suggest a limited structural heterogeneity in those
components actually contributing to TNF responsiveness and identify p60 as acommon receptor
molecule essential for TNF signal transduction. As H398 is a highly effective TNF antagonist
in vitro, it might be useful as a therapeutic agent in the treatment ofTNF-mediated acute toxicity.
T
NF-ca has been recognized as an essential element in the
pathogenesis of several infectious and autoimmune dis-
eases, necessitating the development of substances that an-
tagonize harmful TNF actions (1-3) . Specific membrane
receptors initiate TNF's pleiotropic activities, and thus are
the prime target of selective antagonists . Structural analysis
of these receptors by ligand crosslinking and affinity puri-
fication revealed the existence of a major TNF binding pro-
tein of -85 kD (4-9) . However, recent studies using a va-
riety ofcrosslinking reagents and anti-receptor antibodies have
suggested a greater heterogeneity in TNF receptor molecules
with apparent molecular masses of 55-60, 70, and 80 kD
(10, 11) . These receptor molecules might be expressed in a
cell- or tissue-specific manner (10) . Moreover, lower molec-
ular mass TNF binding proteins have been found in human
serum and urine, and most likely represent soluble forms of
distinct TNF-membrane receptors (12-15) . Accordingly, it
is conceivable that in addition to diversification at the level
of signal transduction, receptor heterogeneity accounts for
the broad spectrum ofTNF bioactivity. To gain information
about the structure/function relationship of the distinct TNF
binding proteins, and in search of antagonists of TNF ac-
tion, we have developed mAbs against affinity-purified TNF
receptor preparations. We describe here an antibody (H398)
that specifically recognizes ahuman 60-kDTNF receptor (p60)
and uniformly acts as a strong antagonist ofTNF action even
on cells that are heterogeneous in TNF receptors . These data
suggest that the p60 TNF receptor is an essential compo-
nent for signal transduction ofTNF responses, whereas TNF
binding to p85 appears on its own not sufficient to elicit a
biological response.
Materials and Methods
Materials.
￿
All reagents, ifnot otherwise stated, were from Sigma
ChemicalCo. (Munich, FRG) . Purified recombinant humanTNF-a
and IFN- .y were kindly provided by G. Adolf, Boehringer Ingel-
heim (Vienna, Austria) .
Cell Lines.
￿
All cell lines used were obtained from American
Type Culture Collection (Rockville, MD) and were maintained in
Click's/RPMI tissue culture medium (Biochrom, Berlin, FRG) sup-
plemented with 5% FCS, 10 mM Hepes, penicillin, and strepto-
mycin (7) . YT cells were a generous gift ofR . Robb (I.E . duPont
de Nemours, Glenolden, PA) .
Production ofmAbs.
￿
About 220 Etg affinity-purified receptor ma-
terial from HL60 cells containingN9 i~g actively binding receptor
were used to immunize a mouse of the BALB/c strain (first injec-
tion [3 Ag] with CFA, second injection with IFA, and a booster
injection with soluble protein alone) . Spleen cells were fused with
NSO cells (16) followed by the usual HAT selection protocol. One
ofthe clones obtained produced an IgG2a able to significantly down-
modulateTNFbinding capacity on HL60 cells. This clone, H398,
was subcloned twice and used to prepare ascites fluid. IgG2a was
purified using a proteinA column (Promab ; Proton, Maidenhead,
England) and used for further studies .
Binding Studies.
￿
TNF and H398 antibody were iodinated by
the lactoperoxidase method, as described, resulting in material
without significant loss in bioactivity and a specific radioactivity
of40-100 NACi/1Ag protein (17) . Determination of specific binding
capacities with iodinated TNF or with purified iodinated H398
antibody were performed in duplicates at various concentrations
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tasl-H398 antibody) . Cells were incubated for 3 h at 0°C in PBS
supplemented with 2% FCS, 10 ttg/ml mouse IgG, and 0.02%
sodium azide . Nonspecific binding was determined in each case
in the presence of a 200-fold excess ofthe respective unlabeled mol-
ecules . Saturation binding studies were analyzed usingtheprogram
Enzfitter (Elsevier, Biosoft, London).
TNF Bioassays .
￿
For determination of antagonistic activity of
mAb H398, the following bioassays have been used . Modulation
ofcell surface antigens was determined by indirect immunofluores-
cence analysis on an EPICSCcytofluorograph (Coulter Electronics
Inc., Krefeld, FRG) as described (18), using the antibodies W6/32,
L243, and antiTac (19) for determination of HLA-A,B,C, HLA-
DR, and IL2R expression, respectively (18, 20) . TNF-mediated
growth inhibition and cytotoxic activity ofTNF were determined
by [3H]thymidine incorporation and crystal violet staining, respec-
tively, according to established protocols (7, 21), and are detailed
in the legends .
Immunoprecipitation andSDS Gel Electrophoresis.
￿
HL60 cells (3
x 108) were surface labeled with '2'I and lysed on ice with 1%
Triton X-100 as described (17) . After removal of a 12,000-g pellet,
the supernatant was precleared with protein A-Sepharose (Phar-
macia Fine Chemicals, Piscataway, NJ) for 2 h andthen incubated
with either 2 1Cg/ml mAb H398 or control antibody for 16 h at
0°C in the presence of protein A-Sepharose and 1 M NaCl ad-
justed topH 8.0. The beadswere washed three times with 20 mM
Tris-HCI, pH 8.0, 1M NaCl, 5mM MgC12, 0.2% Triton X-100,
and 1 mM PMSF, andonce with 50 mM Tris-HCI, pH 7.8, were
heated in sample buffer (5 min, 95°C), and subjected to SDS-PAGE
(7.5% gel) according to Laemmli (22) . Electroelution wasperformed
in an Elucon (Biometra, Gottingen, FRG) with a recovery of60%
of the radioactivity. Electroblotting onto nitrocellulose was car-
ried out in a discontinuous buffer system essentially as described
(17) . The membranes were incubated with 1251TNF (20 ng/ml)
for 2h at room temperature, washed, and exposed to KodakXAR
films .
Crosslinking Studies.
￿
Crosslinking experiments were performed
essentially as described (17) . Cells were incubatedwith 20 ng/ml
1211TNF for 1 h at 0°C and subsequently treated with 1 mM di-
succinimidyl suberate (Pierce Chemical Co., Rockford, IL) for 30
min . After immunoprecipitation with an antiTNF antibody (23),
samples were analyzed by SDS-PAGE and autoradiography.
Results and Discussion
An anti-human TNF receptormAb (H398) was obtained
by immunization of mice with HL60-derived affinity-purified
TNF receptor material . H398 specifically precipitates a 60-
kD membrane protein from lysates of surface-iodinatedHL
60 cells (Fig. 1, lane 2), capable of specific TNF binding,
as demonstrated by subsequent ligand blotting (Fig. 1, lane
7) . Moreover, H398 exhibited high affinity binding to HL
60 cells (Kd = 2.5 x 10 -1°M ; Fig. 2 A) and competed
with
1251TNF binding with half-maximum inhibition at
0.01 ug/ml (Fig. 2 B) . Taken together, these data show that
H398 identifies aTNFmembrane receptor. Westernblot anal-
ysis of H398 immunoprecipitates from whole cell lysates of
HL60 cells revealed, in addition to the60-kD receptor, specific
bands at 45 and -120 kD, suggesting that these products
are antigenically related to p60 and probably represent intra-
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Figure 1 .
￿
H398 antibody defines a 60-kD TNF membrane receptor.
HIT60 cells were surface iodinated, and H398 (lanes 2, 4, 5, and 7) or
control IgG (lanes 1, 3, and 6) immunoprecipitates were prepared from
cell lysates. Separation by SDS-PAGE in the presence (lanes 1 and 2) or
absence (not shown) of 2-ME reveals a specific band of -60 kD. To dem-
onstrate specific TNF binding capacity, which is abolished by reducing
agents (data not shown ; 11), aliquots from the same immunoprecipitates
were subjected to nonreducing SDS-PAGE, and gel pieces in the range
of 50-70 kD were excised . After electroelution, radioactivity was quanti-
tated by scintillation counting (H398 vs. control antibody ; 1,210 specific
cpm) . Thetwo samples were rerun on SDS-PAGE and blotted electropho-
retically onto nitrocellulose membranes before autoradiography (lane 3 :
control antibody, 90-h exposure time; lanes 4 and5 : H398, 90 and 14 h,
respectively) . Subsequently, the nitrocellulose sheets were blotted with
1251-TNF resulting in additional specifically bound radioactivity, as deter-
mined by autoradiography (lane 6, control antibody ; lane 7, H398, both
14-h exposure time) and scintillation counting (7,150 specific cpm com-
pared with 1,210 specific cpm before blotting, see above) .
cellular precursors and/or degradation products (data not
shown) .
Partial competition of 1251-TNF binding, with a plateau
at -60% of total TNFbindingcapacity ofHI760 cells (Fig.
2B, Table 1), is in accordance with the view of the existence
of distinct TNF receptors. Comparativequantitative binding
studies with 1251-labeledTNF and H398 indeed showed ex-
pression of two distinct TNF receptors. Whereas in most
cell lines investigated, the number of H398-defined epitopes
was in therangeofTNF binding sites (calculatedon the basis
of trimeric TNF as ligand), inYT cells and dibutyriccAMP
(DBcAMP)1-pretreated HL60 cells, a clear segregation was
observed (Table 1) . Crosslinking studies further support these
data. In accordance with earlier findings (9), in HL60 cells,
as in most cell lines, an 85-kD protein is found as a major
TNFreceptor protein (Fig. 3) that is not recognized byH398
(Fig. 1) . In addition, in HeLa cells, a distinct crosslinking
product of -78 kD can be revealed (Fig. 3, lane 3), which
'Abbreviation used in this paper: DBcAMP, dibutyric CAMP.a
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Figure 2 .
￿
Saturation binding of 12 51-H398 on HL60 cells and partial
competition of H398 with 1251-TNF binding. (A) Specific 1251-H398
binding of HL60 cells was determined as describedin Material and Methods.
The apparent dissociation constant of H398 binding (Kd = 2 .5 x , 10-10
M) and the number of H398 epitopes (1,556/cell) were calculated from
Scatchard analyses (see inset) . (B) 106 HL60 cells were incubated in dupli-
cates with 20 ng/ml 1 251-TNF and the indicated concentrations of H398
antibody for 3 h at 0°C . Nonspecific binding in the presence ofa 200-fold
excess of unlabeled TNF was 2,150 cpm and is subtracted in the graph.
in HL60 cells is detectable only as a faint band after long
exposures (data not shown ; 10) . The latter is the dominant
and probably exclusive crosslinking product in MCF-7 cells
(Fig. 3, lane 4), most likely composed of monomeric TNF
crosslinked to the H398-defined receptor p60 . Together, these
data show the existence of two distinct TNF receptor pro-
teins of-60 and -85 kD that are coexpressed in several cell
lines of distinct tissue origin .
Evidence for an independent regulation of thesetwoTNF
receptor proteins was obtained in HL60 cells, in whichTNF
binding capacity is under positive control of protein kinase
A (24) . We show here that the DBrAMP-mediated 13-fold
upregulation of TNF binding capacity is associated with a
strong increase in p85 with no change in p60 levels, as re-
vealed from formation of the 100-kD crosslinking product
ofp85 (Fig. 3, lanes 1 and 2) and Scatchard analyses of H398-
defined vs . total TNF receptors, respectively (Table 1) .
The observation ofcompetition ofH398 with TNF binding
prompted studies on the interference of the antibody with
cellular TNF responses . On MCF-7 and HeLa cells, where
TNF binding can be blocked to a large extent, if not totally,
pretreatment with H398 indeed abrogated TNF-induced cy-
totoxicity (Table 1) . Unexpectedly, however, H398 proved
to be a potent TNF antagonist for distinct cellular TNF re-
sponses, even in a cell line in which p60 comprises only a
small portion oftotalTNF receptors. H398 inhibited theTNF-
induced enhancement of IL2Rs (Tac antigen) in YT cells,
though p60-mediatedTNF binding only accounts for -15%
100
Figure 3 . Chemical crosslinking
studies with 1251TNF on different
cell lines reveal two distinct receptor
proteins. Membrane-bound 1251-TNF
was crosslinked with disuccinimidyl
suberate and analyzed by SDS-PAGE
as described in Materials and Methods.
Arrows indicate the two major cross-
linking products of 100 and 78 kD,
respectively .
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￿
H398 antibody is a TNF antagonist . Shown is the dose-
dependent inhibition of TNF-mediated cytostasis on U937 cells (0) (left
axis) and of TNF-mediated enhancement ofHLA-DR expression in Colo
205 cells (O) (right axis) . In both assay systems, the presence of IFN-y
is required to induce the respective TNF responses (18, 27, 28) . Modula-
tion ofTNF cytostatic activity on U937 cells is given in percent growth
inhibition of IFN-y-treated U937 cells (/) (8,191 cpm) . HLA-DR an-
tigen expression in Colo 205 cells is given in arbitrary fluorescence units
on a log scale. Untreated Colo 205 cells areHLA-DR- (mean log fluores-
cence intensity of 54 vs . 52 with control antibody). IFN -'Y induces gene
expression (0) (mean log fluorescence intensity of 121), which is enhanced
byTNF (27) . U937 and Colo 205 cells werecultured for 40 h in the pres-
ence of10 and 0.02 ng/ml ofIFN-y, respectively, with or without 1 ng/ml
TNF and log 10 dilutions of H398 antibody. U937 cells were then pulsed
with [3H]thymidine for 6 h (28). Each value represents the mean of six
replicates (SD <18%) . Colo 205 cells were analyzed forHLA-DR expres-
sion by immunofluorescence flow cytometry.Data represent means of three independent experiments ± SD. TNF and H398 binding sites were calculated from Scatchard analyses of specific
binding data. To quantitate maximum competition of H398 with 1ZSI-TNF, the respective cells were incubated for 3 h at 0°C in triplicates with
40 ng/ml'25I-TNF in the presence and absence of increasing concentrations (0.01-10 Wg/ml) of H398, respectively. Unspecific binding was deter-
mined in the presence of a 200-fold excess of unlabeled TNF. Assessment of antagonistic activity of H398 antibody in TNF bioassays was performed
at TNF concentrations from 1 to 10 ng/ml, dependent on the assay system, in the presence or absence of 10 ttg/ml of H398 antibody. U937 and
Colo 205 cells were treated as described in Fig. 4. HL-60 cells were cultured in six replicates (200 cells per microwell) for 10 d in the presence
of 1 ng/ml TNF, and proliferation was determined by [3H]thymidine incorporation. K562 cells were cultured for 48 h in thepresence of 10 ng/ml
of IFN-.y to induce HLA-A,B,C expression and 3 ng/ml of TNF. HLA-A,B,C antigen expression was determined by immunofluorescence flow
cytometry. Confluent HeLa and MCF-7 cells were cultured in six replicates in the presence of 1 ng/ml TNF and 5 Wg/ml cycloheximide (7 h)
or 2.5 ug/ml cycloheximide (20 h) . Viability of cells was determined by staining with cristal violet as described (21). YT cells were cultured for
24 h in the presence of 10 ng/ml of TNF, and thereafter, expression of the Tac antigen was quantitated by immunofluorescence flow cytometry
using anti-Tac antibody (19). Effects of H398 antibody on TNF-mediated cytotoxicity in murine L929 cells was studied in the standardized assay
system in the presence of 1 ug/ml of actinomycin D (26).
of total TNF binding sites of this cell line (Table 1). Like-
wise, in K562 (Table 1) and Colo 205 cells (Fig. 4), TNF-
mediated enhancement of class I and class II MHC antigen
expression, respectively, was completely inhibited in thepres-
ence of H398. Moreover, TNF-induced cytostasis of U937
(Fig. 4) and HL60 cells (Table 1) was also fully antagonized
by H398 treatment.
The finding that H398 uniformly blocks various gene
regulatory as well as cytostatic andcytotoxicactivities ofTNF
is very intriguing, and suggests that H398 is an antagonist
of TNF action in general. According to this view, p60 must
represent thebiologically relevant TNF receptor or a neces-
sary component thereof, whereas binding of TNF to p85 is
not sufficient to initiate TNF responses. However, it is con-
ceivable that in analogy to the IIr2R system (25), in cells
coexpressing both types of TNFreceptors, p85maycooperate
with p60, e.g., by modulation of ligand binding affinity. Ir-
respective of apossible cooperation with other TNFbinding
proteins, p60 appears essential for TNF receptor function,
suggesting that it mediates a common primary signal across
the membrane. Therefore, p60-specific antibody H398 ap-
pearsavaluable tool to elucidate theseinitial signal transduc-
tion events giving rise to distinct TNF responses. Moreover,
as H398 is a highly effective TNF antagonist, it is poten-
tially useful as a therapeutic agent in the treatment of TNF-
mediated acute toxic effects.
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Table 1. Interference ofH398 with TNFAction and Binding in Comparison with the Expression of TNF Binding Sites vs. H398 Epitopes
Binding sites per cell
Cell line
Percent inhibition
of TNF response Assay system
Percent inhibition of
"II-TNF binding 'ZSI-TNF I'll-H398
±SD ±SD
YT 100 IL-2R expression 15 ± 7 7,116 ± 1,477 911 ± 99
HL-60 100 Growth inhibition 43 ± 14 1,864 ± 412 2,463 ± 457
(untreated cells)
HL-60 ND ND 6 ± 5 24,026 ± 1,114 1,428 ± 168
(cAMP-treated cells)
U937 100 Growth inhibition 40 ± 8 1,439 ± 261 1,727 ± 206
Colo 205 100 HLA-DR expression 20 ± 7 1,770 ± 210 1,250 ± 380
HeLa 100 Cytotoxicity 88 ± 8 4,152 ± 1,075 4,412 ± 1,250
MCF-7 >82 Cytotoxicity 94 ± 5 ND ND
K562 100 HLA-A,B,C expression 16 ± 12 ND ND
L929 <5 Cytotoxicity 0 ND NDReference
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